# Medical Question & Answer

**Sample ID**: 44530e2b-d9c4-4cd0-ade4-7aec21938bc0
**Dataset Index**: 296

---

## Question

Can spironolactone be used to cure bacterial vaginosis?

---

## Answer

> Let's see… What do we have here? The user is asking whether spironolactone can be used to cure bacterial vaginosis. Let's break this down step-by-step. First, I need to think about what the authoritative guidelines list as effective BV treatments. Then, I should verify whether any of the provided documents mention spironolactone for BV at all. Next, I will consider whether spironolactone's mechanism plausibly targets BV pathophysiology. Finally, I will synthesize the evidence and outline clinically appropriate options and why spironolactone does not fit here [^116ecoQF] [^114kX2MY].

> Let me first confirm the standard of care for BV. The CDC and WHO recommend nitroimidazoles or clindamycin as first-line therapies, such as oral metronidazole for 7 days, intravaginal metronidazole gel, clindamycin cream or ovules, and single-dose options like secnidazole or tinidazole; FDA labeling similarly supports metronidazole- and clindamycin-based regimens for BV with documented cure rates and microbiologic efficacy, and none of these guidelines include spironolactone for BV [^116ecoQF] [^114fsSas] [^114kX2MY] [^114n4Gn7] [^116jSkoA] [^114Rr35y] [^112YuMtv] [^115SVHdb] [^1151SPZz].

> Wait, let me verify whether spironolactone is even discussed for BV in the provided evidence base. I systematically checked the documents and see spironolactone only in the context of acne in women, including the SAFA randomized trial and multiple dermatology systematic reviews and expert panels; there are no BV trials, no preclinical BV data, and no guideline endorsements linking spironolactone to BV treatment in any capacity [^111fnaQQ] [^1135W71s] [^115c1F1P] [^116j549X] [^113VSipv] [^117Wfc5r].

> I need to ensure the pharmacology makes sense. BV is a polymicrobial anaerobic dysbiosis with overgrowth of organisms such as Gardnerella and Prevotella and loss of protective lactobacilli, and effective therapy requires antimicrobial activity against anaerobes and restoration of normal flora; spironolactone is a mineralocorticoid receptor antagonist with antiandrogenic effects used for conditions like acne and hirsutism, and it has no established antibacterial activity against BV-associated organisms nor any proven effect on vaginal pH, biofilms, or anaerobic eradication, which represents a mechanistic mismatch for curing BV [^116jSkoA] [^111fnaQQ].

> Hold on, I should double-check that proven BV therapies achieve clinically meaningful cure so I'm not missing a non-antibiotic alternative. FDA-labeled trials and contemporary RCTs demonstrate metronidazole- and clindamycin-based regimens achieve higher clinical and bacteriologic cure versus control, with metronidazole ER showing approximately 72% clinical cure at one month in pivotal trials and single-dose formulations like secnidazole and optimized clindamycin gel regimens also demonstrating efficacy; spironolactone appears nowhere in these BV efficacy data [^116jSkoA] [^113o53sW] [^116dNKcF] [^114M7v4Y].

> Next, I should review recurrence and adjunct strategies to be sure there isn't a role for spironolactone in preventing relapse. Recurrent BV remains common despite initial cure, prompting exploration of male partner treatment and antibiofilm approaches; however, partner treatment RCTs have not shown definitive benefit in intention-to-treat analyses, and antibiofilm strategies remain largely investigational, with none of these lines of research implicating spironolactone as a therapy for BV or recurrence prevention [^113ZE7fJ] [^116DDyx9] [^1114nKdN] [^111wuo2N] [^111aLKtC].

> Hmm, wait a minute — I initially wondered if spironolactone's hormonal effects could indirectly favor Lactobacillus dominance and lower BV risk, but hold on, that's conjecture without supporting data; I should confirm again. Rechecking the guidelines and labeled therapies, there is no endorsement of hormonal agents like spironolactone for BV treatment or prevention, and the pathophysiologic target in BV is bacterial eradication and microbiome normalization via antimicrobials, not androgen blockade [^116ecoQF] [^114kX2MY] [^114n4Gn7].

> Putting this together, I should be explicit: spironolactone cannot be used to cure bacterial vaginosis because it lacks antimicrobial activity, is not studied for BV, and is not recommended by any authoritative guideline; appropriate therapy relies on nitroimidazoles or clindamycin per CDC/WHO guidance, with regimen selection tailored to patient factors, while recognizing recurrence management is an evolving area that still centers on antimicrobial strategies rather than hormonal agents [^116ecoQF] [^114fsSas] [^114kX2MY] [^114n4Gn7].

---

Spironolactone does not cure bacterial vaginosis (BV) because it has **no antibacterial activity** against BV-associated organisms. BV is treated with **antibiotics** such as metronidazole, clindamycin, or tinidazole [^116ecoQF], which are recommended by clinical guidelines [^114kX2MY]. Spironolactone is an aldosterone antagonist used for conditions like hypertension, heart failure, and acne, and is **not indicated for BV**. Using spironolactone for BV is ineffective and may **delay appropriate care** [^114fsSas].

---

## Mechanism of action of spironolactone

Spironolactone is a potassium-sparing diuretic and aldosterone antagonist that **blocks mineralocorticoid receptors**, reducing sodium and water retention while increasing potassium retention. It is used for:

- Hypertension
- Heart failure
- Hyperaldosteronism
- Acne vulgaris (anti-androgenic effects) [^111fnaQQ]

Spironolactone has **no antibacterial or antimicrobial activity** and does not affect bacterial growth or biofilm formation.

---

## Pathophysiology of bacterial vaginosis

BV is characterized by a **shift from Lactobacillus-dominated flora to anaerobes** such as Gardnerella vaginalis, Atopobium vaginae, Prevotella spp., and Mobiluncus spp [^111aLKtC]. This dysbiosis results in:

- Increased vaginal pH
- Formation of bacterial biofilms [^111HNDm7]
- Persistent infection and high recurrence rates [^116DDyx9] [^111nhBpc]

Effective BV treatment requires **antibiotics** that target these anaerobes and disrupt biofilms [^114fsSas].

---

## Recommended treatments for bacterial vaginosis

Current clinical guidelines **recommend the following antibiotic regimens** for BV:

| **Antibiotic** | **Dosage and duration** | **Route of administration** |
|-|-|-|
| Metronidazole | 500 mg twice daily for 7 days | Oral |
| Metronidazole gel | 0.75% once daily for 5 days | Intravaginal |
| Clindamycin cream | 2% once daily at bedtime for 7 days | Intravaginal |
| Tinidazole | 2 g once daily for 2 days or 1 g once daily for 5 days | Oral |
| Secnidazole | 2 g single dose | Oral |

---

These regimens **effectively eradicate BV-associated bacteria** [^116jSkoA] and reduce recurrence.

---

## Clinical evidence regarding spironolactone and bacterial vaginosis

There is **no clinical evidence** or published studies supporting spironolactone for BV. Spironolactone is **not included in any clinical guidelines** or recommendations for BV management [^116ecoQF].

---

## Potential risks and side effects of spironolactone

Using spironolactone for BV **may cause adverse effects**, including [^111fnaQQ]:

- Hyperkalemia (elevated potassium levels) [^1135W71s]
- Menstrual irregularities
- Breast tenderness or gynecomastia [^115c1F1P]
- Gastrointestinal disturbances
- Fatigue and dizziness

These risks **outweigh any hypothetical benefit**, given the lack of antibacterial activity.

---

## Conclusion and recommendations

Spironolactone does not **cure BV** and has **no antibacterial activity** against BV-associated organisms. BV should be treated with **recommended antibiotics** such as metronidazole, clindamycin, or tinidazole [^114fsSas]. Using spironolactone for BV is ineffective and may **delay appropriate treatment**, thereby increasing the risk of recurrence and complications [^116ecoQF].

---

## References

### Sexually transmitted infections treatment guidelines, 2021 [^114fsSas]. MMWR. Recommendations and reports (2021). High credibility.

Regarding medical management for bacterial vaginosis, specifically concerning antibiotic therapy, CDC 2021 guidelines recommend any of the following regimens as second-line therapy in patients with BV:

- **Clindamycin regimens**:
	- Clindamycin 300 mg PO BID for 7 days
	- Clindamycin ovules 100 mg intravaginally once at bedtime for 3 days

- **Alternative antibiotics**:
	- Secnidazole 2 g PO granules in a single dose
	- Tinidazole 2 g PO once daily for 2 days
	- Tinidazole 1 g PO once daily for 5 days

---

### Recommendations for the treatment of Trichomonas vaginalis, Mycoplasma genitalium, Candida albicans, bacterial vaginosis and human papillomavirus (anogenital warts) [^114kX2MY]. Geneva: World Health Organization (2024). High credibility.

Regarding medical management for bacterial vaginosis, more specifically with respect to antibiotic therapy, WHO 2024 guidelines recommend offering metronidazole 400 mg or 500 mg PO BID for 7 days in adult and adolescent patients (including pregnant women) with BV.

---

### Sexually transmitted infections treatment guidelines, 2021 [^116ecoQF]. MMWR. Recommendations and Reports (2021). High credibility.

Regarding the medical management of bacterial vaginosis, the CDC 2021 guidelines recommend offering any of the following regimens as first-line therapy in patients with BV:

- **Metronidazole 500 mg**: Administer PO BID for 7 days.
- **Metronidazole gel 0.75%**: Use one full applicator (5 g) intravaginally, once daily for 5 days.
- **Clindamycin cream 2%**: Apply one full applicator (5 g) intravaginally at bedtime for 7 days.

---

### Antibiofilm agents for the treatment and prevention of bacterial vaginosis: A systematic narrative review [^1114nKdN]. The Journal of Infectious Diseases (2024). Low credibility.

The ongoing search for new therapeutics against bacterial vaginosis (BV) has been complicated by an incomplete understanding of its pathophysiology and the role of biofilms. Numerous promising agents are being investigated, and findings indicate that the application of anti-BV biofilm agents may bring a potential breakthrough in the treatment of BV. However, this is still an evolving field predominantly in the preclinical stages of research. With concerns about antibiotic resistance, action is urgently needed to move the study of these diverse antibiofilm agents into animal and human trials, although the absence of optimal animal models for BV is slowing the momentum of this much-needed development.

---

### Dequalinium chloride for the treatment of vulvovaginal infections: A systematic review and meta-analysis [^113zKJ5z]. Journal of Lower Genital Tract Disease (2024). Low credibility.

Women of reproductive age frequently experience vulvovaginal infections and vaginitis. The most common etiologies are vulvovaginal candidiasis (VVC), bacterial vaginosis (BV), desquamative inflammatory vaginitis/aerobic vaginitis, and trichomoniasis. Various treatment options are available for these infections, such as specific antimicrobial or antiseptic agents. Dequalinium chloride (DQC) is a local antiseptic agent with a broad antimicrobial and antifungal spectrum. Multiple studies suggest that DQC is an efficient treatment for vaginal infections; however, it is not widely recommended as a first-line treatment. This systematic review and meta-analysis aims to evaluate the efficacy of DQC compared with that of standard treatment.

- **Methods**: Our systematic review was conducted according to the PRISMA guidelines. PubMed/MEDLINE, EMBASE, CENTRAL, and clinicaltrials.org were searched to retrieve relevant reports up to October 2022.

- **Results**: Four randomized controlled studies and one observational study were included in this review. Overall, DQC showed noninferiority to the reference treatments for BV and VVC, and to the evaluated treatment options for desquamative inflammatory vaginitis/aerobic vaginitis. For BV and VVC, this could also be confirmed in a meta-analysis including three randomized controlled studies. No serious adverse events were reported in any of these studies.

- **Conclusions**: Dequalinium chloride offers a safe, well-tolerated, and efficient treatment option for vulvovaginal infections of different etiologies. However, further studies are needed to…

---

### Treatment of bacterial vaginosis before 28 weeks of pregnancy to reduce the incidence of preterm labor [^114H3Y9u]. International Journal of Gynaecology and Obstetrics (2019). Low credibility.

Controversy exists regarding the benefits of treating bacterial vaginosis (BV) during pregnancy to reduce the incidence of preterm labor (PTL).

- **Objectives**: To evaluate whether treatment of BV with vaginal clindamycin or oral metronidazole before 28 weeks of pregnancy reduces PTL incidence.

- **Search strategy**: PubMed, Scopus, Web of Science, Science Direct, CENTRAL, and SciELO databases were searched until December 30, 2017. Search terms included "bacterial vaginosis" and "preterm labor". No language restrictions were applied.

- **Selection criteria**: Randomized clinical trials that evaluated treatment of BV with clindamycin or metronidazole to reduce PTL incidence.

- **Data collection and analysis**: The risk of PTL was evaluated by the odds ratio (OR) and 95% confidence interval (CI). Dichotomous data from each study were combined for meta-analysis using the Mantel-Haenszel model.

- **Main results**: Nine reports were included in the systematic review, with eight reports included in the meta-analysis. No reduction in the incidence of PTL was found for either metronidazole (OR 0.94, 95% CI 0.71–1.25) or clindamycin (OR 1.01, 95% CI 0.75–1.36).

- **Conclusions**: Use of oral metronidazole or vaginal clindamycin to treat BV before 28 weeks of pregnancy did not reduce the incidence of PTL. PROSPERO registration: CRD42018086173.

---

### Relationship of specific vaginal bacteria and bacterial vaginosis treatment failure in women who have sex with women [^1147XBwM]. Annals of Internal Medicine (2008). Low credibility.

Bacterial vaginosis frequently persists after treatment, yet the role of newly defined bacterial vaginosis-associated bacteria (BVAB), which have a specificity for this condition of 97% or greater, has not been assessed.

- **Objective**: To define risks for bacterial vaginosis persistence, including pretreatment detection of specific vaginal bacteria, among women reporting sex with women.

- **Design**: Observational cohort study.

- **Setting**: University-based research clinic.

- **Patients**: 335 women aged 16 to 29 years reporting sex with at least 1 woman in the past year. Participants were recruited through advertisements and provider referral.

- **Intervention**: Bacterial vaginosis was treated with intravaginal metronidazole gel (0.75%), 37.5 mg nightly for 5 nights.

- **Measurements**: Species-specific 16S recombinant DNA polymerase chain reaction assays targeting 17 bacterial species were applied to vaginal fluid obtained at baseline. Tests of cure by clinical criteria, Gram stain analysis, and repeated polymerase chain reaction assays of vaginal fluid were performed 1 month after treatment. Interim behaviors were assessed using computer-assisted self-interview.

Results showed that of the 335 women, 24% also reported sex with men within 3 months before enrollment. Among these, 131 (39%) had bacterial vaginosis. Of the 120 (92%) women who returned for follow-up, the incidence of persistent bacterial vaginosis was 26%. The persistence rate was statistically significantly higher in women with baseline detection of 3 Clostridiales bacteria, designated as BVAB1 (risk ratio, 2.0 [95% CI, 1.1 to 4.0]) and BVAB2.

---

### Bacterial vaginosis: drivers of recurrence and challenges and opportunities in partner treatment [^1165g122]. BMC Medicine (2021). Low credibility.

What we can learn from past male-partner treatment trials

More than 60 years ago, researchers and clinicians held the view that the syndrome of BV was sexually transmitted, or at least, associated with sex. The findings from the six male-partner treatment trials conducted in the 1980s and 1990s have been extensively reviewed, but we briefly summarize the findings with the aim of understanding the outcomes.

One of the challenges when assessing the effectiveness of partner treatment is that the trials utilized very different combinations of antibiotic treatments for differing durations, and there was no published data to inform what treatments may be optimal for men. These trials had major trial-related limitations, including small sample sizes, absence of power calculations, inconsistent and non-standard methods to diagnose BV in women, use of single-dose and non-standard treatments for women (which we now know are suboptimal), lack of data on treatment adherence, and high attrition. Another key difference between the trials was that the clinical endpoints were measured anywhere from 7 to 10 days to 12 weeks post-randomization. The timing of the endpoint may be critical in determining if an intervention is efficacious. Among couples counseled to abstain from sex, BV endpoints measured immediately post-treatment are more likely to reflect the efficacy of female-only treatment rather than the effect of treating the male on BV. In contrast, endpoints measured following a longer period of time post-treatment may be undermined by the introduction of u.

---

### Prevotella and gardnerella are associated with treatment failure following first-line antibiotics for bacterial vaginosis [^111nhBpc]. The Journal of Infectious Diseases (2023). High credibility.

We conducted a secondary analysis of vaginal microbiota data and accompanying clinical and behavioral data collected from women who participated in three clinical trials conducted at the Melbourne Sexual Health Centre (MSHC), Australia, that evaluated new interventions for improving bacterial vaginosis (BV) cure. These trials included Strategies to Prevent BV (SToPBV), StepUp-1, and StepUp-2. The parent trials have been described elsewhere.

- **Study populations and procedures**: In brief, SToPBV was an open-label randomized controlled trial of combined oral contraceptive pill use following first-line antibiotic treatment to prevent BV recurrence. StepUp-1 and StepUp-2 were open-label single-arm pilot studies that assessed the acceptability and tolerability of concurrent male partner treatment for BV and its impact on the genital microbiota of couples. The supplementary material details the interventions assessed in the parent studies.

Across the three studies, women presenting to MSHC were eligible to participate if they were diagnosed with BV (defined as ≥ 3 Amsel criteria and Nugent score [NS] = 4–10) and received first-line treatment. The treatment included oral metronidazole 400 mg twice daily for 7 days, or if contraindicated, clindamycin 2% vaginal cream applied intravaginally nocte for 7 nights, or metronidazole 0.75% gel applied intravaginally nocte for 5 nights. Additional study-specific eligibility criteria were applied. Of note, women were eligible for SToPBV if they were not currently using hormonal contraception and had no combined oral contraceptive pill–related contraindications. Women were eligible for the StepUp studies based on similar criteria.

---

### Oral spironolactone for acne vulgaris in adult females: A hybrid systematic review [^1135W71s]. American Journal of Clinical Dermatology (2017). Low credibility.

This systematic review endorses key aspects of expert opinion with hard data while providing new insights. It highlights existing important gaps in evidence regarding the use of oral spironolactone for managing acne in women. Issues include defining the optimal dose and dosing regimen to maximize benefits and minimize risks, identifying the lowest effective dose, determining if concomitant therapies are necessary and what these should be, recognizing which acne types are likely to respond, and comparing spironolactone's effectiveness with standard therapies.

Interestingly, several acne guidelines and treatment recommendations include spironolactone based on consensus and/or expert opinion. However, other guidelines either do not mention spironolactone or specifically state it is regarded as ineffective, not recommended, or that there is insufficient evidence to support its use. Despite purporting to be evidence-based, these guidelines have failed to identify the majority of studies included in this systematic review.

Although five relevant studies were unobtainable at the time of writing (two of which were likely duplicate publications of included case series), the review is confident that all randomized controlled trials (RCTs) evaluating spironolactone for acne in women were retrieved, and no clinical trial evidence was overlooked. Until higher quality evidence becomes available, guideline developers must rely on recommendations largely based on expert experience or consensus from expert panels.

---

### No. 211-screening and management of bacterial vaginosis in pregnancy [^1118uXGb]. Journal of Obstetrics and Gynaecology Canada (2017). High credibility.

Regarding specific circumstances for bacterial vaginosis, particularly in pregnant patients, the SOGC 2017 guidelines recommend testing for and treating BV to achieve symptom resolution in symptomatic pregnant patients.

---

### Antibiofilm agents for the treatment and prevention of bacterial vaginosis: A systematic narrative review [^111HNDm7]. The Journal of Infectious Diseases (2024). High credibility.

Bacterial vaginosis (BV) is difficult to eradicate due to BV biofilms protecting BV bacteria (Gardnerella, Prevotella, and other genera). With the growing understanding of biofilms, we systematically reviewed the knowledge on the efficacy of anti-BV biofilm agents.

- **Methods**: We searched the literature in the Scopus, Medline, and Embase databases for empirical studies investigating substances for the treatment of BV biofilms or prevention of their recurrence and their efficacy and/or safety.

- **Results**: Of 201 unique titles, 35 satisfied the inclusion criteria. Most studies (89%) reported on preclinical laboratory research on the efficacy of experimental antibiofilm agents (80%) rather than their safety. Over 50% were published within the past 5 years. Agents were classified into seven groups: antibiotics, antiseptics, cationic peptides, enzymes, plant extracts, probiotics, and surfactants/surfactant components. Enzymes and probiotics were most commonly investigated. Earlier reports of antibiotics having anti-BV biofilm activity have not been confirmed. Some compounds from other classes demonstrated promising anti-BV biofilm efficacy in early studies.

- **Conclusions**: Further research is anticipated on successful antibiofilm agents. If confirmed as effective and safe in human clinical trials, they may offer a breakthrough in BV treatment. With rising antibiotic resistance, antibiofilm agents will significantly improve the standard of care for BV management.

---

### Metronidazole [^116jSkoA]. U.S. Food and Drug Administration (2023). High credibility.

Bacterial vaginosis (BV) is a clinical syndrome that results from a replacement of the normal, Lactobacillus-dominant flora with several other organisms, including Gardnerella vaginalis, Mobiluncus spp, Mycoplasma hominis, and anaerobes such as Peptostreptococcus spp and Bacteroides spp.

- **Clinical studies**: Metronidazole extended-release tablets were studied in patients with BV in two randomized, multicenter, well-controlled, investigator-blind clinical trials. A total of 557 otherwise healthy, nonpregnant patients with BV were randomized to treatment with metronidazole extended-release tablets once a day for 7 days (n = 270) or 2% clindamycin vaginal cream one applicator full (5 grams) once a day for 7 days (n = 287). The primary efficacy endpoint for each treatment regimen was defined as clinical cure assessed at 28 to 32 days post-therapy. Clinical cure was defined as a return to normal of the vaginal pH (≤ 4.5), the absence of a "fishy" amine odor, and the absence of clue cells.

- **Study results**: At one month post-therapy, the pH of the vagina returned to normal earlier and in a greater percentage of patients in the metronidazole extended-release tablets treatment group when compared to the 2% clindamycin vaginal cream group; 72% vs. 65%, respectively. Likewise, metronidazole extended-release tablets restored the normal Lactobacillus-predominant vaginal flora in a larger percentage of patients at one month post-therapy when compared to the 2% clindamycin treated group; 74% vs. 63%.

---

### Treatment of male sexual partners of women with bacterial vaginosis: A randomized, double-blind, placebo-controlled trial [^112CQfWe]. Clinical Infectious Diseases (2021). Low credibility.

The study aimed to determine if the treatment of male sexual partners of women with recurrent bacterial vaginosis (BV) using oral metronidazole twice per day for seven days (i.e. multidose metronidazole) significantly decreased BV recurrence rates in the female partners.

- **Methods**: This was a multicenter, two-arm, double-blind, placebo-controlled study. Women with recurrent BV, diagnosed by Amsel and Nugent criteria, were enrolled. Multidose metronidazole for seven days was dispensed to women. Male partners were randomized to receive either placebo or multidose metronidazole for seven days and were asked to refrain from unprotected sex for 14 days. Female follow-up visits were conducted on day 21 and at 8 and 16 weeks. Male follow-up visits occurred between days 14 and 21. BV cure was defined as meeting 0–2 Amsel criteria and achieving a Nugent score of 0–6 in the female partner, with the primary endpoint assessed at 16 weeks.

- **Results**: A total of 214 couples were enrolled. In the intent-to-treat population, there was no significant difference between treatment arms for the primary outcome. BV treatment failure occurred in 81% of women in the metronidazole arm and 80% in the placebo arm through the third follow-up visit (P > .999). However, women whose male partners adhered to the study medication were less likely to experience treatment failure (adjusted relative risk, 0.85; 95% CI, 0.73–0.99; p = 0.035). This finding remained consistent in post hoc comparisons within the metronidazole arm.

- **Conclusions**: Overall, this study did not find that male partner treatment with multidose metronidazole significantly reduces BV recurrence in female partners, although women whose partners adhered to multidose metronidazole treatment were less likely to fail treatment.

---

### Bacterial vaginosis: drivers of recurrence and challenges and opportunities in partner treatment [^116DDyx9]. BMC Medicine (2021). High credibility.

Since these two systematic reviews were published, we have results from a recently conducted RCT. Schwebke et al. treated women with recurrent bacterial vaginosis (reBV) with the first-line regimen of 7-day oral metronidazole 500mg bid, and their male sexual partners were randomised to concurrent treatment with the same regimen or an oral placebo. This trial was the most thoroughly designed, addressing the limitations of prior trials with sufficient sample size, clear power calculations, appropriate randomization methods, blinding, and inclusion of data on antibiotic adherence. However, the trial was stopped early due to futility, as the primary intention-to-treat analysis showed partner treatment did not improve cure by 16 weeks post-randomization.

Even though these findings appear to be another notch against male-partner treatment, there are important considerations to note. The overall recurrence rate was 80% in women in both groups, which is higher than previous studies. This may suggest the study population had underlying risk factors placing them at high risk of recurrence, or persistent BV biofilm refractory to oral metronidazole. Further, post hoc analyses revealed that among couples where the man was 100% adherent to metronidazole treatment, the female partners were significantly less likely to recur (73% vs. 97% recurrence in women whose partners were 100% vs. < 100% adherent, respectively, p < 0.001). These findings suggest a modest effect of oral treatment in highly adherent males, but it is important to consider that oral therapy alone may also not be sufficient.

---

### Nuvessa [^112YuMtv]. U.S. Food and Drug Administration (2023). High credibility.

A single, randomized, double-blind, vehicle-controlled clinical trial was conducted to evaluate the efficacy of Nuvessa. Subjects had a clinical diagnosis of bacterial vaginosis, defined by the presence of a homogenous vaginal discharge that (a) had a pH ≥ 4.7, (b) emitted a "fishy" amine odor when mixed with a 10% KOH solution ("whiff" test), and (c) contained clue cells ≥ 20% of the total vaginal epithelial cells. In addition, to be eligible for analysis, subjects must have had a Gram stain Nugent score ≥ 4 and have been negative for N. gonorrhoeae and C. trachomatis. Non-pregnant females, at least 18 years of age, were randomized 1:1 to either Nuvessa or Vehicle Gel and instructed to administer the study drug once at bedtime. Two hundred ninety-two (292) Nuvessa subjects and 285 Vehicle Gel subjects were eligible for the analysis.

Clinical cure was defined as (a) return of normal physiological discharge, (b) negative KOH "whiff" test, and (c) clue cell < 20% of the total vaginal epithelial cells at the test of cure visit (between 21 to 30 days post-treatment). Bacteriological cure was defined as a Nugent score of < 4, and therapeutic cure was defined as clinical cure and bacteriological cure. Nuvessa demonstrated statistically significantly higher cure rates than Vehicle Gel as measured by clinical cure, bacteriological cure, and therapeutic cure.

- **Clinical cure and bacteriological cure at Day 7**: Clinical cure at Day 7 was achieved by a statistically significantly greater proportion of subjects in the Nuvessa group compared to subjects in the Vehicle Gel group.

---

### Antibiotics for treating bacterial vaginosis in pregnancy [^116Dgvug]. The Cochrane Database of Systematic Reviews (2013). High credibility.

Bacterial vaginosis is an imbalance of the normal vaginal flora characterized by an overgrowth of anaerobic bacteria and a lack of the normal lactobacillary flora. Women may have symptoms of a characteristic vaginal discharge but are often asymptomatic. Bacterial vaginosis during pregnancy has been associated with poor perinatal outcomes, particularly preterm birth (PTB). Identification and treatment may reduce the risk of PTB and its consequences.

- **Objectives**: To assess the effects of antibiotic treatment of bacterial vaginosis in pregnancy.

- **Search methods**: We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (31 May 2012), searched cited references from retrieved articles, and reviewed abstracts, letters to the editor, and editorials.

- **Selection criteria**: Randomised trials compared antibiotic treatment with placebo or no treatment, or compared two or more antibiotic regimens in pregnant women with bacterial vaginosis or intermediate vaginal flora, whether symptomatic or asymptomatic and detected through screening.

- **Data collection and analysis**: Two review authors independently assessed trials for inclusion, evaluated trial quality, and extracted data. We contacted study authors for additional information.

- **Main results**: We included 21 trials of good quality, involving 7847 women diagnosed with bacterial vaginosis or intermediate vaginal flora. Antibiotic therapy was shown to be effective at eradicating bacterial vaginosis during pregnancy (average risk ratio (RR) 0.42; 95% confidence interval (CI) 0.31 to 0.56; 10 trials, 4403 women; random-effects, T² = 0).

---

### Prevotella and gardnerella are associated with treatment failure following first-line antibiotics for bacterial vaginosis [^1166sJ5S]. The Journal of Infectious Diseases (2023). High credibility.

Participant characteristics and factors associated with BV recurrence

Table 1 summarizes baseline characteristics and sexual practices of the 121 women included in analyses. The pooled cohort of women had a median age of 28 years (interquartile range, 25–32 years). Approximately half of the participants were born in Australia or New Zealand (56/121 [46%]), 24% were born in Europe (most commonly the United Kingdom and Ireland), and 22% were born in Asia (most commonly China, Hong Kong, Taiwan, and Southeast Asia). At baseline, 87 women (72%) reported having a regular sexual partner (RSP) (most of whom were male [83/87]), 26 (21%) reported hormonal contraceptive use, and 13 (11%) had an intrauterine device in situ. Most women (89/121 [74%]) had a history of BV. Some characteristics differed between the StepUp and SToPBV cohorts (i.e. having an RSP at baseline, baseline contraceptive practices, and post-treatment sexual practices), which was primarily due to differences in the eligibility criteria applied in each study.

Of the 121 women, 16 (13% [95% confidence interval {CI}, 8%–21%]) experienced BV recurrence. Only one characteristic differed significantly between recurrence and cure cases. Women who reported sex with an untreated RSP during follow-up were significantly more likely to experience BV recurrence compared to women who had no RSP (9/28 [32%] vs. 3/44 [7%], P = 0.008) and women who had an RSP treated through StepUp-1/2 (9/28 [32%] vs. 4/49 [8%], P = 0.011). Interestingly

---

### Nuvessa [^115SVHdb]. U.S. Food and Drug Administration (2023). High credibility.

Nuvessa is indicated for the treatment of bacterial vaginosis in females 12 years of age and older. It is a nitroimidazole antimicrobial used for this purpose.

---

### Bacterial vaginosis: A practical review [^111aLKtC]. JAAPA (2017). High credibility.

The following constitutes key background information on bacterial vaginosis:

- **Definition**: Bacterial vaginosis (BV), previously referred to as Gardnerella vaginitis, is a disease resulting from the overgrowth of normal vaginal bacterial flora.

- **Pathophysiology**: BV is idiopathic; however, sexual transmission has been implicated. It is associated with fluctuations in vaginal microbiota, with a relative increase in Gardnerella vaginalis, Atopobium vaginae, Prevotella species, and Mobiluncus species, along with a decrease in lactobacilli.

- **Epidemiology**: In the United States, about 7.4 million cases of BV occur yearly. In nonpregnant women with symptomatic vaginal discharge, the overall prevalence of BV is 24.4% based on Nugent's scoring system.

- **Disease course**: BV is characterized by milky and malodorous vaginal discharge, resulting in vulvovaginal discomfort and irritation. It has a strong association with preterm birth, first-trimester miscarriage in women undergoing IVF, chorioamnionitis, amniotic-fluid infection, endometritis after childbirth or abortion, and infections after hysterectomy.

- **Prognosis and risk of recurrence**: BV has a high recurrence rate of up to 50% within a year of treatment.

---

### Bacterial vaginosis: Drivers of recurrence and challenges and opportunities in partner treatment [^116Ac4vJ]. BMC Medicine (2021). Low credibility.

Recommended first-line antimicrobial treatments, such as metronidazole or clindamycin, provide broad anaerobic coverage and are administered orally or intravaginally. These regimens display similar efficacy, curing approximately 70–85% of women with BV within one month; however, more than 50% experience recurrence of symptoms and BV on microscopy within six months. The low rate of sustained cure not only highlights our incomplete understanding of the pathogenesis of BV recurrence, but also exacerbates women's distress and frustration, leading to repeated presentations to health services or the adoption of unproven home remedies.

Factors contributing to recurrence may include the persistence of a BV-associated biofilm, failure to recolonize the vagina with lactobacilli, reinfection from an untreated partner, and host genetic and/or immune factors. Frustratingly for both clinicians and patients, the contribution of reinfection and vaginal relapse cannot be separated, as the clinical presentation of both mechanisms is identical. Point-of-care laboratory tests cannot resolve this issue yet, and molecular methods, including next-generation sequencing, are unable to identify a unique or specific microbial signature to separate the two routes of recurrence.

While persistence or resistance of BVAB or BV biofilm following antibiotic therapy is likely a dominant mechanism among some women, a robust body of evidence supports the exchange of both optimal and detrimental bacteria between partners during sexual activity. These data suggest that reinfection of women with pathogenic bacteria can contribute to the recurrence of symptoms.

---

### Current treatment of bacterial vaginosis-limitations and need for innovation [^1166JtZJ]. The Journal of Infectious Diseases (2016). Low credibility.

Practitioners and patients alike widely recognize the limitations of therapeutic approaches to the treatment of bacterial vaginosis (BV). Options remain extremely limited, and our inability to prevent the frequent and often relentless symptomatic recurrences of BV and to reduce serious sequelae, such as preterm delivery, remains an acknowledged but unresolved shortcoming. Our incomplete understanding of the pathophysiology of this unique form of vaginal dysbiosis has been a significant impediment to developing optimal treatment and prevention approaches.

New drugs have not been forthcoming and are not likely to be available in the immediate future. Hence, reliance on the optimal use of available agents has become essential as improvised and often unproven regimens are implemented. In this review, we explore the limitations of currently recommended therapies, with a particular focus on the contribution of reinfection and pathogen persistence to BV recurrence and the development of interventions that target these mechanisms.

Ultimately, to achieve sustained cure and effectiveness against BV-associated sequelae, it is possible that we will need approaches that combine antimicrobials with biofilm-disrupting agents and partner treatments in those at risk of reinfection.

---

### Oral spironolactone for acne vulgaris in adult females: A hybrid systematic review [^115c1F1P]. American Journal of Clinical Dermatology (2017). Low credibility.

The management of acne in adult females is problematic, with many experiencing a history of treatment failure and some having a predisposition to androgen excess. Alternatives to oral antibiotics and combined oral contraceptives (COCs) are required.

- **Objective**: Our aim was to conduct a hybrid systematic review of the evidence for benefits and potential harms of oral spironolactone in the management of acne in adult females.

- **Methods**: The review was conducted according to a previously published protocol. Three reviewers independently selected relevant studies from the search results, extracted data, assessed the risk of bias, and rated the quality of the evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach.

- **Results**: Ten randomized controlled trials (RCTs) and 21 case series were retrieved. All trials were assessed as being at a "high risk" of bias, and the quality of evidence was rated as low or very low for all outcomes. Apart from one crossover trial that demonstrated statistical superiority of a 200 mg daily dose versus inflamed lesions compared with placebo, data from the remaining trials were unhelpful in establishing the degree of efficacy of lower doses versus active comparators or placebo. Menstrual side effects were significantly more common with the 200 mg dose; frequency could be significantly reduced by concomitant use of a COC. Pooling of results for serum potassium supported the recent recommendation that routine monitoring is not required in this patient population.

This systematic review highlights the need for further research with a higher level of evidence to better understand the efficacy and safety of oral spironolactone in treating acne vulgaris in adult females.

---

### Clindesse [^1151SPZz]. U.S. Food and Drug Administration (2025). High credibility.

Two clinical studies were conducted to evaluate the efficacy of Clindesse for the treatment of bacterial vaginosis. A clinical diagnosis of bacterial vaginosis was defined by the presence of a homogeneous vaginal discharge that (a) has a pH of greater than 4.5, (b) emits a "fishy" amine odor when mixed with a 10% KOH solution, and (c) contains clue cells on microscopic examination. Gram's stain results consistent with a diagnosis of bacterial vaginosis include (a) markedly reduced or absent Lactobacillus morphology, (b) predominance of Gardnerella morphotype, and (c) absent or few white blood cells.

In a randomized, double-blind, placebo-controlled clinical study involving 144 non-pregnant female patients aged 18 to 64 with a baseline Nugent score ≥ 4, Clindesse demonstrated statistically significantly higher cure rates over placebo as measured by therapeutic cure, clinical cure, and Nugent score cure, assessed at 21–30 days after administration of the drug. Therapeutic cure was a composite endpoint which required both clinical cure and Nugent score cure. Clinical cure required normal vaginal discharge, vaginal pH < 4.7, < 20% clue cells on wet mount preparation, and a negative "whiff" test (detection of amine odor on addition of 10% KOH solution to a sample of the vaginal discharge). A Nugent score of 0–3 was considered a Nugent score cure. The Nugent scoring is based on microscopic examination of the Gram's stained vaginal smears for quantification of specific bacterial morphotypes. Cure rates were consistently higher for Clindesse compared to the placebo group.

---

### Antibiofilm agents for the treatment and prevention of bacterial vaginosis: A systematic narrative review [^114Cnv2i]. The Journal of Infectious Diseases (2024). Low credibility.

Strengths and limitations of this review: To our knowledge, this is the first review to detail research evidence on different anti-BV biofilm treatments. These findings inform clinicians about developments in the field and, in turn, offer their patients hope of a long-term cure.

Several limitations of this review should be acknowledged. While publication bias was not specifically assessed, it was noted that the majority of publications reported on effective compounds. It is quite likely that significant research work, which has found investigative compounds ineffective, remains unpublished and was consequently not captured by this review. Additionally, the heterogeneity of study designs made comparisons among findings difficult, since observations in laboratory cultures and animal models are not often reflected in human subject research.

---

### Antibiofilm agents for the treatment and prevention of bacterial vaginosis: A systematic narrative review [^1113DUBd]. The Journal of Infectious Diseases (2024). Low credibility.

In recent years, the increased understanding of BV biofilms has stimulated research on how to improve the standard of care through the development of antibiofilm agents. Currently, a range of antibiofilm agents is being actively explored, including various antiseptics, cationic peptides, enzymes, plant extracts, probiotics, and surfactants that could assist in the penetration of the biofilm structure. However, there are no literature reviews summarizing the existing evidence from anti-BV biofilm research.

---

### Antimicrobial resistance associated with the treatment of bacterial vaginosis [^114Geo5n]. American Journal of Obstetrics and Gynecology (2004). High credibility.

This study was undertaken to evaluate antimicrobial susceptibility of vaginal anaerobic bacteria before and after the treatment of bacterial vaginosis.

- **Study design**: A randomized clinical trial of 119 nonpregnant women with bacterial vaginosis was conducted. Participants received either intravaginal metronidazole for 5 days or clindamycin for 3 days. Women had one baseline and three follow-up visits, at which quantitative vaginal cultures were performed. Anaerobic isolates underwent antimicrobial susceptibility testing.

- **Results**: Complete susceptibility data was available for 95 women (47 metronidazole and 48 clindamycin). Of the 1059 anaerobic bacterial isolates, less than 1% demonstrated resistance to metronidazole. In contrast, 17% showed baseline clindamycin resistance, and 53% demonstrated resistance to clindamycin after therapy. Women exposed to clindamycin (but not metronidazole) exhibited high frequencies (80%) of clindamycin-resistant anaerobic bacteria that persisted for 90 days after treatment.

- **Conclusion**: Treatment of bacterial vaginosis with clindamycin is associated with significant evidence of antimicrobial resistance among vaginal anaerobic bacteria. This may increase the vaginal reservoir of macrolide-resistant bacteria.

---

### Bacterial vaginosis: drivers of recurrence and challenges and opportunities in partner treatment [^112u1cXw]. BMC Medicine (2021). Low credibility.

Evidence to support sexual transmission of the BV syndrome: There is longstanding evidence supporting the contribution of sexual transmission to the pathogenesis of bacterial vaginosis (BV). In the 1950s, Gardner and Dukes first characterized BV and hypothesized that "… husbands must be treated simultaneously if recurrences by reinfection are to be prevented". When vaginal discharge was transferred from women with BV to those without, 11 out of 15 women developed clinical signs and microbiological features of BV, indicating that the BV syndrome is infectious.

Initially, Gardnerella vaginalis was isolated from women with BV and hypothesized to be a new STI responsible for the syndrome. However, when 13 'healthy' women were inoculated with pure cultures of G. vaginalis (incubated for 24 hours prior to inoculation and in the stationary phase of growth), only one developed BV. In a subsequent study using fresh cultures of G. vaginalis incubated for 12 hours prior to inoculation and in the late logarithmic phase of growth, 5 out of 9 women developed the BV syndrome. This finding suggests that the phase of growth and environmental signals may control the expression of bacterial virulence factors, conferring a greater pathogenic potential to G. vaginalis, a finding supported by more recent evidence.

Supporting the initial hypothesis that G. vaginalis is the etiologic agent responsible for BV, it was isolated from the urethra of 91 out of 101 husbands of women with BV, but only from 1 out of 38 male medical students. Successive studies also isolated G. vaginalis from the urethra of male partners of women with BV.

---

### Antibiofilm agents for the treatment and prevention of bacterial vaginosis: A systematic narrative review [^115dnEGU]. The Journal of Infectious Diseases (2024). Low credibility.

Predefined inclusion and exclusion criteria guided the screening of identified articles. Included articles were peer-reviewed primary research publications of any study design that examined the efficacy and safety of therapeutic compounds in the treatment or prevention of BV biofilms. We included only publications in Chinese, English, German, Russian, and Ukrainian, which we could review without requiring translation.

Excluded were articles of non-primary research, conference abstracts, ongoing clinical trials with no available results, and case studies or series, as well as studies of treatment cost, acceptability, or attitudes. Also excluded were articles that did not report extractable data pertaining to the aim of this review.

Primary screening of titles, abstracts, and full text was performed by two reviewers using Covidence systematic review software (Veritas Health Innovation). Disagreements were discussed and finalized. See the PRISMA flowchart for our selection process.

Data were extracted into Microsoft Excel. Four groups of variables were extracted:

- **Publication description**: Journal, year of publication, country.
- **Study aim**: Prevention or eradication, population, age range, biofilm species.
- **Research method**: Study design, sample size, therapeutic agent, comparator.

---

### Antibiofilm agents for the treatment and prevention of bacterial vaginosis: A systematic narrative review [^112NtRH5]. The Journal of Infectious Diseases (2024). Low credibility.

Supplementary materials are available at The Journal of Infectious Diseases online. These materials consist of data provided by the author to benefit the reader and are not copyedited. The responsibility for the contents of all supplementary data lies solely with the authors. Any questions or comments regarding potential errors should be directed to the author.

---

### Oral spironolactone for acne vulgaris in adult females: A hybrid systematic review [^117Wfc5r]. American Journal of Clinical Dermatology (2017). Low credibility.

The protocol for this review was published in PROSPERO with the accession number 42016038496.

- **Search strategies**: Electronic searches were conducted between 10 and 15 May 2016 and included the Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, Science Citation Index, and LILACS. The search strategy for MEDLINE and EMBASE is shown in Appendix 1 (electronic supplementary material). The following trials registers were searched using the search terms spironolactone AND acne or 'polycystic ovarian syndrome': meta Register of Controlled Trials; US National Institutes of Health Ongoing Trials Register; Australian New Zealand Clinical Trials Registry; World Health Organization International Clinical Trials Registry Platform; EU Clinical Trials Register. The reference lists of all identified RCTs and key review articles were checked for citations to potentially relevant studies. No language or date restrictions were applied.

Outputs of searches were imported into Rayyan to facilitate sorting, and full-text copies of all potentially eligible studies were obtained. Two authors (AE and ZF) independently assessed the full-text papers and resolved any disagreements on the eligibility of included studies through discussion and consensus, or through a third party (EvZ).

The review included randomized controlled trials (RCTs) in females of any ethnicity over 18 years of age with acne vulgaris of the face and/or trunk, or polycystic ovarian syndrome if acne status or severity was measured as an outcome. Case series were included if they provided supplementary evidence on the benefits or side effects.

---

### Bacterial vaginosis: Drivers of recurrence and challenges and opportunities in partner treatment [^113ZE7fJ]. BMC Medicine (2021). High credibility.

Partner treatment trials targeting male partners

There are an additional set of challenges when recruiting couples to male-partner treatment trials. Women are often reluctant to disclose their symptoms to men and may require educational material and support to increase their confidence in discussing their bacterial vaginosis (BV) and the associated morbidities with their partner. Motivating male partners to participate is also made more difficult by the fact that most men do not experience symptoms themselves. This was highlighted by men participating in partner treatment trials, who reported BV to have little impact on themselves beyond their concerns for their partner's health, self-esteem, and confidence. Interestingly, some men identified that the diagnosis of BV in their female partner led to improved communication within the partnership about sex and sexual health, and that accepting partner treatment showed they were committed to the relationship and could be a supportive partner. Further research to identify the factors that may motivate male participants to engage in BV treatment trials is required.

Fundamentally, we also still do not know what the most appropriate and effective antibiotic agents are to use in male partners. Nearly all the randomized controlled trials (RCTs) to evaluate partner treatment used oral metronidazole. Metronidazole, a nitroimidazole antibiotic with broad activity against anaerobic bacteria, achieves 1-month cure rates of over 80% among women. Less than 1% of anaerobic bacteria isolated from women pre-treated with a 5-day intravaginal metronidazole regimen demonstrated resistance.

---

### Single-dose, bioadhesive clindamycin 2% gel for bacterial vaginosis: A randomized controlled trial [^113o53sW]. Obstetrics and Gynecology (2022). High credibility.

The objective of this study was to assess the efficacy and safety of a single-dose vaginal clindamycin gel for the treatment of bacterial vaginosis.

- **Methods**: We conducted a double-blind, placebo-controlled, randomized study comparing clindamycin gel with placebo in a 2:1 ratio. Entry into the study required a clinical diagnosis of bacterial vaginosis, characterized by all four of Amsel's criteria, and the absence of other genital infections. Nugent scores of 7–10 were required for efficacy assessment, in accordance with the updated 2019 U.S. Food and Drug Administration guidance. Patients were evaluated at screening, days 7–14, and days 21–30 (test of cure). Clinical cure was defined as the resolution of three of the four Amsel's criteria. Bacteriologic cure was defined as a Nugent score lower than 4. Therapeutic cure was defined as both clinical and bacteriologic cure. The primary outcome was the clinical cure at the test-of-cure visit. Secondary endpoints included clinical cure at days 7–14, and both bacteriologic and therapeutic cures at days 7–14 and test of cure. The sample size included 188 patients in the clindamycin group and 94 patients in the placebo group, providing 90% power to detect a statistically significant difference (P = 0.05, 2-tailed).

- **Results**: Participants were seen between July 9, 2020, and November 12, 2020. Of the 307 randomized women, 56.0% were Black, and 88.3% reported having one or more previous episodes of bacterial vaginosis. In the modified intention-to-treat population, 70.5% of patients in the clindamycin group and 35.6% in the placebo group achieved clinical cure at the test of cure (primary outcome), with a difference of 34.9 (95% CI 19.0–50.8), as did 77.5% of patients in the clindamycin group compared to 42.6%.

---

### Prevotella and gardnerella are associated with treatment failure following first-line antibiotics for bacterial vaginosis [^11249m4D]. The Journal of Infectious Diseases (2023). High credibility.

Analysis of compositions of microbiomes with bias correction (ANCOM-BC) version 1.6.2 was used to identify differentially abundant taxa between recurrence and cure cases pre- and immediately post-treatment. ANCOM-BC analyses were adjusted for laboratory method, and taxa that were present in ≤ 10% of samples were excluded. Bacterial taxa identified as differentially abundant by ANCOM-BC with a P value < 0.05 were further explored using logistic regression. Logistic regression examined the association between BV recurrence and the centered log-ratio (CLR)–transformed abundance of each taxon, adjusting for laboratory method and partner type/treatment status.

Finally, using an approach similar to Lee et al, we explored the relationship between BV recurrence and the ratio of nonoptimal to optimal bacteria present in the vagina pre- and post-treatment. The following ratios were examined: (i) total BV-associated bacteria to Lactobacillus spp (BVAB: Lactobacillus), (ii) Gardnerella to Lactobacillus iners (Gardnerella: L. iners), and (iii) total pathobionts to Lactobacillus spp (pathobionts: Lactobacillus). Pathobionts are organisms that may become inflammatory and pathogenic under specific conditions, and a high pretreatment pathobiont load has been associated with metronidazole treatment failure. Supplementary Table 1 lists the bacterial taxa included in each group. Ratios were calculated using log10-transformed relative abundance data, and the association between BV recurrence and bacterial ratios was evaluated using logistic regression models, adjusted as described above.

---

### Antibiotics for treating bacterial vaginosis in pregnancy [^111Y9niF]. The Cochrane Database of Systematic Reviews (2007). Low credibility.

Bacterial vaginosis is characterized by an imbalance of the normal vaginal flora, involving an overgrowth of anaerobic bacteria and a lack of the normal lactobacillary flora. During pregnancy, bacterial vaginosis has been associated with poor perinatal outcomes, particularly preterm birth (PTB). Identification and treatment may reduce the risk of PTB and its consequences.

- **Objectives**: To assess the effects of antibiotic treatment of bacterial vaginosis in pregnancy.

- **Search strategy**: We searched the Cochrane Pregnancy and Childbirth Group's Trials Register (May 2006).

- **Selection criteria**: Randomized trials comparing antibiotic treatment with placebo or no treatment, or comparing two or more antibiotic regimens in pregnant women with bacterial vaginosis or intermediate vaginal flora.

- **Data collection and analysis**: Two review authors assessed trials and extracted data independently. We contacted study authors for additional information.

- **Main results**: We included fifteen trials of good quality, involving 5888 women. Antibiotic therapy was effective at eradicating bacterial vaginosis during pregnancy (Peto odds ratio (OR) 0.17, 95% confidence interval (CI) 0.15 to 0.20; 10 trials, 4357 women). Treatment did not reduce the risk of PTB before 37 weeks (Peto OR 0.91, 95% CI 0.78 to 1.06; 15 trials, 5888 women), or the risk of preterm prelabour rupture of membranes (PPROM) (Peto OR 0.88, 95% CI 0.61 to 1.28; four trials, 2579 women). However, treatment before 20 weeks' gestation may reduce the risk of preterm birth less than 37 weeks (Peto OR 0.63, 95% CI 0.48 to 0.84; five trials, 2387 women).

---

### Effects of probiotics on the recurrence of bacterial vaginosis: A review [^116cUDt9]. Journal of Lower Genital Tract Disease (2014). Low credibility.

Bacterial vaginosis (BV) is a common cause of genital discomfort in women of reproductive age, leading to numerous complications. The standard treatment involves metronidazole and clindamycin; however, this regimen does not prevent recurrence, a primary concern for patients. Women with BV have significantly fewer lactobacilli in the vagina compared to healthy women. Consequently, efforts have been made to normalize vaginal flora through oral or vaginal administration of lactobacilli. This study aims to review clinical evidence regarding the efficacy of probiotics in preventing and treating BV.

Published randomized controlled trials (RCTs) were searched in PubMed, Science Direct, and the Cochrane Database between 1990 and 2011 using search terms such as "bacterial vaginosis", "urinary tract infection", "lactobacillus", and "probiotics".

Orally consumed probiotics are believed to ascend to the vaginal tract after excretion from the rectum. Vaginal administration allows direct replacement of probiotics in place of unhealthy vaginal microbiota, facilitating occupation of specific adhesion sites at the epithelial surface of the urinary tract. This process results in the maintenance of a low pH and the production of antimicrobial substances, such as acids and hydrogen peroxide. Administering Lactobacillus acidophilus, Lactobacillus rhamnosus GR-1, and Lactobacillus fermentum RC-14 at a dose of at least 10 CFU/day for two months has demonstrated positive outcomes.

---

### 2018 European (IUSTI/WHO) International Union against sexually transmitted infections (IUSTI) World Health Organisation (WHO) guideline on the management of vaginal discharge [^1179gpny]. International Journal of STD & AIDS (2018). High credibility.

Regarding screening and diagnosis for bacterial vaginosis, more specifically with respect to diagnostic criteria, the IUSTI/WHO 2018 guidelines recommend using the Hay-Ison criteria during microscopic evaluation for the diagnosis of BV.

---

### Prevotella and gardnerella are associated with treatment failure following first-line antibiotics for bacterial vaginosis [^116zjz7h]. The Journal of Infectious Diseases (2023). High credibility.

ANCOM-BC was used to identify bacterial taxa that were differentially abundant pre- and posttreatment between recurrence and cure cases. Pretreatment, the mean abundance of Prevotella spp (representing Prevotella amplicon sequence variants that were not able to be classified at the species level) was significantly higher in women who experienced recurrence compared to those who were cured at 1 month posttreatment (log fold change [LFC] = 1.44, standard error [SE] = 0.56, P = 0.011). Immediately posttreatment, the mean abundance of Gardnerella was increased in recurrence versus cure cases (LFC = 1.90, SE = 0.86, P = 0.028).

Conversely, the mean abundance of both L. crispatus and Lactobacillus fornicalis was decreased in women who experienced recurrence compared to those who did not (L. crispatus LFC = −1.55, SE = 0.40, P = 0.0001; L. fornicalis LFC = −1.19, SE = 0.34, P = 0.0006). There was no significant difference in the abundance of L. iners between recurrence and cure cases at day 0 (LFC = 0.08, SE = 0.71, P > .05) or day 8 (LFC = −1.60, SE = 1.02, P > .05).

ANCOM-BC findings were mostly consistent with findings from a second differential abundance analysis method. Supplementary Table 2 presents the prevalence and relative abundance of taxa identified as differentially abundant by ANCOM-BC. Of note, L. crispatus was present in low relative abundance both pretreatment and immediately posttreatment in most participants, except for 8 cure cases who had an L. crispatus relative abundance > 50% at day 8.

---

### Women presenting to emergency departments with vaginitis should be offered single-dose empirical treatment [^116dNKcF]. Academic Emergency Medicine (2025). High credibility.

In 2017, the U.S. Food and Drug Administration (FDA) approved a 2-g single-dose oral secnidazole (two 1-g packets) for the treatment of bacterial vaginosis (BV) and trichomoniasis (TV), which is currently listed as an alternative BV treatment option in U.S. CDC guidelines. Clinical trials among women with symptomatic vaginitis compared metronidazole, tinidazole, and secnidazole, including single-dose regimens, to treat BV and TV.

For BV, when compared with metronidazole 500 mg BID for seven days, both 2-g single-dose tinidazole and 2-g single-dose secnidazole demonstrated similar cure rates to metronidazole. Another trial comparing single doses of secnidazole, tinidazole, and metronidazole to treat BV found that tinidazole had a significantly greater clinical cure rate than metronidazole, but secnidazole did not, further supporting the efficacy of single-dose tinidazole. Across all trials for BV, 2-g single-dose tinidazole demonstrated clinical cure rates of 83%–100%.

Unlike FDA guidance for comparative noninferiority trials to evaluate new antibiotics to treat other common infections, guidance for BV antimicrobial approval specifies a placebo-controlled superiority trial. Tinidazole was FDA-approved in 2004 based on a placebo-controlled trial that demonstrated the efficacy of both 2 g daily for two days and for five days. Earlier placebo-controlled trials and many comparative studies of a single 2-g dose of tinidazole were conducted outside the U.S.

---

### Treatment considerations for bacterial vaginosis and the risk of recurrence [^1117pJbh]. Journal of Women's Health (2009). Low credibility.

Recommended regimens for the treatment of bacterial vaginosis (BV) have similar efficacy; thus, the choice of treatment should consider additional factors such as the risk of BV recurrence and side effect profiles. The purpose of this study was to investigate BV recurrence rates and rates of acquiring vulvovaginal candidiasis (VVC) after different BV treatments in a commercially insured population.

- **Methods**: Private administrative insurance claims from 2004 to 2006 were used. Study subjects were continuously enrolled females, 12–50 years of age, who filled prescriptions for BV treatment (n = 32,268). The four BV treatments (single-dose clindamycin vaginal cream (2%), multiple-dose clindamycin vaginal regimens, vaginal metronidazole, and oral metronidazole) were compared for rates of BV recurrence and VVC after treatment using multivariate analyses. Covariates included sociodemographic and clinical characteristics.

- **Results**: Overall, the rates of BV recurrence (2.7%) and VVC post-treatment (2.9%) were low. Women treated with single-dose clindamycin vaginal cream (2%) showed no significant difference from women treated with oral metronidazole in the likelihood of BV recurrence. However, women who received other vaginal treatments were significantly more likely to experience BV recurrence compared with women who received oral metronidazole (p < 0.01). Moreover, women treated with single-dose clindamycin vaginal cream (2%) and vaginal metronidazole were significantly less likely to have VVC compared with those treated with oral metronidazole (p < 0.01).

---

### Antibiofilm agents for the treatment and prevention of bacterial vaginosis: A systematic narrative review [^1131FLM7]. The Journal of Infectious Diseases (2024). Low credibility.

Bacterial vaginosis (BV) is difficult to eradicate due to BV biofilms protecting BV bacteria such as Gardnerella, Prevotella, and other genera. With the growing understanding of biofilms, we systematically reviewed the knowledge on the efficacy of anti-BV biofilm agents.

We searched literature in the Scopus, Medline, and Embase databases for empirical studies investigating substances for the treatment of BV biofilms or prevention of their recurrence and their efficacy and/or safety.

Of 201 unique titles, 35 satisfied the inclusion criteria. Most studies (89%) reported on preclinical laboratory research on the efficacy of experimental antibiofilm agents (80%) rather than their safety. Over 50% were published within the past 5 years. Agents were classified into seven groups: antibiotics, antiseptics, cationic peptides, enzymes, plant extracts, probiotics, and surfactants/surfactant components. Enzymes and probiotics were most commonly investigated. Earlier reports of antibiotics having anti-BV biofilm activity have not been confirmed. Some compounds from other classes demonstrated promising anti-BV biofilm efficacy in early studies.

Further research is anticipated on successful antibiofilm agents. If confirmed as effective and safe in human clinical trials, they may offer a breakthrough in BV treatment. With rising antibiotic resistance, antibiofilm agents will significantly improve the standard of care for BV management.

---

### Secnidazole treatment of bacterial vaginosis: A randomized controlled trial [^117PdSop]. Obstetrics and Gynecology (2017). Low credibility.

To evaluate secnidazole as a single oral dose treatment for bacterial vaginosis, a phase 2 randomized, double-blind, placebo-controlled study was conducted.

- **Methods**: In this study, women with bacterial vaginosis who met all Amsel criteria (discharge; pH 4.7 or greater; 20% or greater clue cells; positive whiff test) were randomized in equal groups at 24 U.S. centers to receive either 1 or 2 g of secnidazole, compared with placebo. The primary endpoint was clinical cure, defined as normalization of discharge, amine odor, and clue cells 21–30 days after treatment. Secondary endpoints included microbiologic cure, defined as a Nugent score of 0–3, and therapeutic cure, defined as meeting criteria for both clinical and microbiologic cure. The modified intent-to-treat was used for efficacy analyses and included all randomized patients who met the enrollment criteria. Assuming a clinical cure rate of 40% in the active groups and 15% in the placebo group, a sample size of 52 patients per group provided approximately 80% power to detect a significant difference between groups at the .05 level (two-sided) using a Cochran-Mantel-Haenszel test.

- **Results**: Between May and September 2014, 215 patients were enrolled. In the intent-to-treat population, the clinical cure rate was 65.3% for the 2-g group, 49.3% for the 1-g group, and 19.4% for the placebo group. The modified intent-to-treat population included 188 women (median age 33 years; 32% with four or more bacterial vaginosis episodes in the previous year; 54% black) with baseline Nugent scores of 4 or greater.

---

### Oral spironolactone for acne vulgaris in adult females: A hybrid systematic review [^116j549X]. American Journal of Clinical Dermatology (2017). Low credibility.

Data extraction was conducted using piloted forms, with risk of bias assessments and analyses carried out independently by three authors. Any disagreements were resolved by consensus. Risk of bias assessments for the RCTs were made using the Cochrane domain-based risk of bias tool, supporting conclusions regarding the overall quality of evidence in the review. Data were analyzed using RevMan version 5.3. Dichotomous outcomes were expressed as risk ratios (RRs) and reported with their associated 95% confidence intervals (CI), while continuous outcomes were reported as mean differences (MDs) with 95% CI.

Attempts, although only partially successful, were made to obtain missing trial details by contacting the lead investigators of the studies. The protocol specified that data would be reanalyzed according to the intention-to-treat (ITT) principle; however, for the majority of trials, this was not possible due to inadequate or incomplete reporting. Therefore, in general, the per-protocol (PP) population was used. Analyses of side effect rates were conducted using the ITT population with and without acne. For numbers included in each type of analysis, see Electronic Supplementary Table 1.

When available, and unless otherwise stated, assessments at month three were used as the basis of comparison between studies. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) software (GRADEpro GDT) was used to rate the quality of evidence from RCTs for the individual outcomes and to produce summary of findings tables.

---

### Metronidazole [^114Rr35y]. U.S. Food and Drug Administration (2023). High credibility.

**Indications and usage**: Metronidazole extended-release 750 mg tablets are indicated for the treatment of bacterial vaginosis (BV) in non-pregnant women. To minimize the development of drug-resistant bacteria and maintain the effectiveness of metronidazole extended-release tablets and other antibacterial drugs, these tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

---

### Bacterial vaginosis: Drivers of recurrence and challenges and opportunities in partner treatment [^112S4V3C]. BMC Medicine (2021). High credibility.

Many of the previous partner trials opted for stat 2g doses of oral metronidazole to improve adherence, and adherence is essential to the success of any intervention; however, the short duration of activity of this single dose may have had limited impact on the male genital microbiota. Newer single-dose nitroimidazoles approved for the treatment of BV, such as 2g oral secnidazole, have similar efficacy to metronidazole but a longer half-life and thus may be more suited to partner treatment. However, secnidazole and tinidazole have similar resistance patterns to metronidazole, and other drug classes or combinations of antimicrobials may be required to cover candidate BV pathogens.

Clindamycin, which is commonly used in women with a contraindication to nitroimidazoles but also used first-line, is a lincosamide antibiotic with broad-spectrum activity against Gram-positive cocci as well as anaerobic Gram-positive and Gram-negative bacteria. Clindamycin has been shown to have greater efficacy than the nitroimidazoles against A. vaginae, Gardnerella spp., and Mobiluncus spp. Planktonic clinical isolates of Gardnerella exhibit a relatively higher susceptibility rate and lower resistance rate to clindamycin compared to metronidazole, suggesting clindamycin may be more optimal for reducing the abundance of Gardnerella.

While the effectiveness of metronidazole and clindamycin in clearing BV-associated bacteria (BVAB) from women is still debated, data is needed to show if these agents are effective on BVAB in men. Newer biofilm-disrupting agents, for example, dequalinium chloride and TOL-463, also warrant exploration.

---

### Solosec [^114M7v4Y]. U.S. Food and Drug Administration (2022). High credibility.

**Recent major changes**: The recent major changes include updates to the "Indications and Usage" section for bacterial vaginosis, effective January 2022, and for trichomoniasis, also effective January 2022. Additionally, the "Dosage and Administration" section was updated in June 2021. Finally, changes to the "Contraindications" section were made in December 2021.

---

### Recommendations for the treatment of Trichomonas vaginalis, Mycoplasma genitalium, Candida albicans, bacterial vaginosis and human papillomavirus (anogenital warts) [^114n4Gn7]. Geneva: World Health Organization (2024). High credibility.

Regarding medical management for bacterial vaginosis, specifically concerning antibiotic therapy, WHO 2024 guidelines recommend considering the following options if oral metronidazole is unavailable, adherence to multiple doses is a significant concern, or if vaginal creams are preferred:

- **Metronidazole 0.75% gel**: Intravaginally for 7 days.
- **Tinidazole 2 g PO**: As a single dose, except during pregnancy.
- **Clindamycin 300 mg BID**: For 7 days.
- **Clindamycin 2% gel 5 g**: Intravaginally once daily for 7 days.
- **Secnidazole 2 g PO**: As a single dose.

---

### What's new in bacterial vaginosis and trichomoniasis [^115iKS42]. Infectious Disease Clinics of North America (2005). Low credibility.

Use of biochemical profiles and new molecular microbiologic methodologies is transforming our understanding of bacterial vaginosis (BV). Most importantly, there is a recognition of different subgroups of women with BV who are at variable risk of certain obstetric and gynecologic complications. New diagnostic tests may soon be available that will allow women to test self-obtained specimens. However, the treatment of BV has lagged, although innovative methods appear to be helpful in managing diseases.

---

### Bacterial vaginosis: Drivers of recurrence and challenges and opportunities in partner treatment [^117VSfPt]. BMC Medicine (2021). Low credibility.

It is clear that therapies solely directed at women have failed to achieve a high rate of sustained cure. By continuing to ignore the potential risk of sexual transmission and reinfection when evaluating the efficacy of treatments, the effectiveness of these strategies is likely to be consistently underestimated. When managing a patient with bacterial vaginosis (BV), incorporating the regular partner who may be a source of reinfection provides an opportunity to impact treatment outcomes. We need to continue to assess how antimicrobials change the genital microbiomes of both women with BV and their partners to ensure the most effective regimens are utilized.

Furthermore, to overcome the shortcomings of past partner treatment RCTs, we need innovative ways to engage women with BV and their partners to ensure the recruitment of monogamous couples and promote adherence to treatment. Continued research into the pathogenicity of bacteria shared between couples may assist us in developing new treatment strategies, as well as provide evidence to support partner treatment as an adjunctive therapy to improve health outcomes for women.

---

### Prevotella and Gardnerella are associated with treatment failure following first-line antibiotics for bacterial vaginosis [^1115LXWu]. The Journal of Infectious Diseases (2023). Low credibility.

The study explores the diversity metrics of the vaginal microbiota in women who experienced bacterial vaginosis recurrence compared to those who remained cured at one month post-enrollment. The analysis includes nonmetric multidimensional scaling plots of the overall composition of the vaginal microbiota before treatment and immediately after treatment. Box plots provide a visual representation of bacterial diversity, measured using the Shannon diversity index, comparing the microbiota of cure and recurrence cases both before and after treatment.

- **Compositional changes**: Presented using box plots, these changes in the vaginal microbiota are measured through Bray–Curtis distances calculated between paired pretreatment and immediate posttreatment samples, highlighting differences between cure and recurrence cases.

- **Abbreviations**: The study uses terms such as ANOSIM (analysis of similarity) and NMDS (nonmetric multidimensional scaling) to facilitate the interpretation of results.

Associations between bacterial vaginosis recurrence and the characteristics of the vaginal microbiota pretreatment and immediately posttreatment are further detailed in the study's analysis.

---

### No. 211-screening and management of bacterial vaginosis in pregnancy [^1158rmmU]. Journal of Obstetrics and Gynaecology Canada (2017). High credibility.

Regarding specific circumstances for bacterial vaginosis, particularly in pregnant patients, the SOGC 2017 guidelines recommend obtaining repeated testing one month after treatment to ensure that a cure was achieved.

---

### A phase 3, multicenter, prospective, open-label study to evaluate the safety of a single dose of secnidazole 2 g for the treatment of women and postmenarchal adolescent girls with bacterial vaginosis [^113Zoh3X]. Journal of Women's Health (2018). Low credibility.

A novel formulation of secnidazole is under development in the United States for the treatment of bacterial vaginosis (BV). Efficacy and safety of other formulations of secnidazole have been reported. The objective of this study is to evaluate the safety of a single-dose oral granule formulation of secnidazole in a U.S. population of women with BV.

- **Methods**: In this open-label study, patients were enrolled based on the following criteria: off-white, thin, homogeneous vaginal discharge; vaginal pH ≥ 4.7; presence of ≥ 20% clue cells; and a positive potassium hydroxide whiff test. Eligible patients received a single dose of secnidazole 2g at baseline. Patients were contacted on days 8–10 and were assessed for safety at an end-of-study visit (days 21–30). Additional endpoints included investigator assessment of the need for additional treatment and a post hoc analysis of clinical response to treatment.

- **Results**: Of 321 patients, 283 (88.2%) completed the study. The mean age was 32 ± 8.5 years; most patients were white (51.4%) or black/African American (46.1%). Most (79.1%) reported ≤ 3 episodes of BV in the past year. The overall number of treatment-emergent adverse events (TEAEs) was 95 (29.6%), of which 53 (16.5%) were treatment-related. Common treatment-related TEAEs were vulvovaginal mycotic infection (5.3%), nausea (4.4%), and dysgeusia (3.1%). The proportion of patients not requiring additional BV treatment, as assessed by investigators, was 72.5%.

- **Conclusions**: Single-dose secnidazole 2g was well tolerated, with a low overall number of TEAEs, most of which were mild.

---

### Bacterial vaginosis: Drivers of recurrence and challenges and opportunities in partner treatment [^111fm2df]. BMC Medicine (2021). Low credibility.

Partner treatment trials targeting female partners

Despite bacterial vaginosis (BV) being common among women who have sex with women (WSW), no partner treatment trials enrolling female couples have been conducted. As mentioned above, the majority (74–95%) of female couples have been shown to be concordant for the presence or absence of BV. If a female index case is enrolled in a partner treatment trial, it is highly likely that her female partner will be concordant for the presence of BV. Enrolling female couples would therefore provide an opportunity to determine the effectiveness of partner treatment in both members of the partnership.

However, female-partner treatment brings a unique set of additional challenges. Enrolling BV-concordant couples in a blinded randomized partner treatment trial would mean that only half of the female partners would be treated for BV at enrollment, as the rest would be randomized to a placebo. The concept of a placebo arm for women may not be accepted by participants or clinicians. Apprehension surrounding the ethics of non-treatment could be mitigated by considering firstly, that it has not been shown that treating BV prevents adverse outcomes, only symptoms; and if one of the partners has asymptomatic BV at enrollment, treatment would not currently be recommended. FDA guidance around BV treatment trials also states that a placebo can be used as a comparator for the control arm, and recent BV treatment trials have done so. Even if partner treatment was accepted, in order to measure clinically meaningful cure, follow-up to 3–4 months is required, and it is quite likely that concerns around possible…

---

### Impact of oral metronidazole treatment on the vaginal microbiota and correlates of treatment failure [^115gKorY]. American Journal of Obstetrics and Gynecology (2020). Low credibility.

Metronidazole is the first-line treatment for bacterial vaginosis, but cure rates are suboptimal and recurrence rates are high.

- **Objectives**: To evaluate the impact of a standard course of oral metronidazole treatment (500 mg twice per day for 7 days) on the vaginal microbiota of Rwandan bacterial vaginosis patients using microscopy and 16S rRNA gene sequencing, and to evaluate correlates of treatment failure.

- **Study design**: HIV-negative, nonpregnant women aged 18–45 years with bacterial vaginosis and/or Trichomonas vaginalis (N = 68) were interviewed and sampled before and after metronidazole treatment. They were also screened, and treated if applicable, for other urogenital infections. The vaginal microbiota was assessed by Gram stain Nugent scoring, Illumina 16S rRNA HiSeq sequencing (relative abundances), and BactQuant 16S gene quantitative polymerase chain reaction (estimated concentrations). Only women with a pretreatment Nugent score of 7–10 and a valid posttreatment Nugent score (N = 55) were included in metronidazole treatment failure analyses, with treatment failure defined as a posttreatment Nugent score of 4–10.

- **Results**: The bacterial vaginosis cure rate by Nugent scoring was 54.5%. The mean total vaginal bacterial concentration declined from 6.59 to 5.85 log 10/μL (P < 0.001), which was mostly due to a reduction in mean bacterial vaginosis-associated anaerobes concentration (all bacterial vaginosis-associated anaerobe taxa combined) from 6.23 to 4.55 log 10/μL (P < 0.001). However, only 16.4% of women had a bacterial vaginosis anaerobes concentration reduction.

---

### Antibiofilm agents for the treatment and prevention of bacterial vaginosis: A systematic narrative review [^112fqYRd]. The Journal of Infectious Diseases (2024). Low credibility.

The aim of this review is to summarize evidence on a range of therapeutic agents with potential activity against BV biofilms.

---

### Bacterial vaginosis: Drivers of recurrence and challenges and opportunities in partner treatment [^116xEuEg]. BMC Medicine (2021). Low credibility.

It is plausible that both penile skin and urethral carriage of BVAB need to be targeted if we are to achieve sufficient clearance of BVAB from the male genitalia and impact reinfection in women. Two pilot partner treatment trials have targeted BVAB in men for 7 days at the distal urethra with 400mg metronidazole bid, and at the sub-preputial space and coronal sulcus with topical 2% clindamycin cream applied bid. Treatment had an immediate effect on the composition of the penile-skin and urethral microbiota, with a decrease in the prevalence and abundance of BVAB; however, this change was not sustained at 1–3 months. Despite the re-emergence of BVAB in men, the female partners of treated males experienced a significant and sustained decrease in the prevalence and abundance of BVAB to endpoint. Although not powered to detect the effect of partner treatment, the pooled BV recurrence rate among the 50 couples undergoing treatment across both trials was only 8% at 1 month, and only 17% among the 29 couples followed to 3 months. Both are lower recurrence rates than would normally be expected in sexually active couples where a history of BV was common, as in other trials where recurrence among couples ranged from 40 to 80%.

These data raise important questions: how effective does partner treatment need to be at reducing BVAB in men, and for what duration do the organisms need to be suppressed to elicit a positive and sustained result in the female? Effective male-partner treatment may only need to disrupt the continued cycle of exposure to BVAB for a short period.

---

### Optimizing the trial design for a comparative effectiveness study of spironolactone versus oral antibiotics for women with acne: A Delphi consensus panel [^113VSipv]. Journal of Drugs in Dermatology (2020). Low credibility.

For women with acne, the condition often persists into adulthood, with over 50% of women reporting acne between the ages of 20–29 and over 35% of women reporting acne between the ages of 30–39. While mild acne can usually be managed with topical medications, moderate to severe acne often requires treatment with systemic medications such as oral antibiotics, spironolactone, and isotretinoin.

Although oral antibiotics are the most common systemic medication prescribed for women with moderate to severe acne, spironolactone may represent a safe and effective therapeutic alternative that can decrease reliance on oral antibiotics for the treatment of acne. However, while the use of spironolactone is increasing, oral antibiotics are still prescribed 3 to 5 times more often than spironolactone.

---

### Antibiofilm agents for the treatment and prevention of bacterial vaginosis: A systematic narrative review [^111wuo2N]. The Journal of Infectious Diseases (2024). High credibility.

Various potential bacterial vaginosis (BV) biofilm removal treatments are currently being actively investigated. We grouped these treatments into seven classes: antibiotics, antiseptics, cationic peptides, enzymes, plant extracts, probiotics, and surfactants/surfactant components. Within the last five years, enzymes and probiotics have been most investigated, though these substances are still in early stages of development with their efficacy yet to be demonstrated through human trials. The growing knowledge about BV biofilms is anticipated to stimulate research in this area.

In vivo biofilms contain multiple BV-associated bacterial species, but some are nonculturable in the laboratory setting. In general, laboratory studies tended to use single-species Gardnerella vaginalis biofilms, which do not reflect the multispecies biofilm conditions in vivo. This limitation was noted by a number of authors within their articles. Several publications attempted to use multispecies biofilm models, noting a higher treatment resistance when compared with single-species biofilms. Additionally, safety and tolerability of the treatment were not adequately measured in most studies. Future research should prioritize the testing of these agents in biofilm models that better approximate in vivo conditions and also measure safety and tolerability through clinical trials.

Antibiotic treatments have always been the standard of care for BV. Narrow-spectrum antibiotics have a selective mechanism of action and target specific species of bacteria while minimally affecting other bacterial populations.

---

### Effectiveness of spironolactone for women with acne vulgaris (SAFA) in England as well as Wales: Pragmatic, multicentre, phase 3, double blind, randomised controlled trial [^111fnaQQ]. BMJ (2023). High credibility.

The study SAFA was published by Miriam Santer and colleagues in 2023 in the journal BMJ. This study focuses on acne vulgaris. The trial question was: what is the effect of spironolactone in female patients with acne vulgaris?

- **Study design**: Multi-center, double-blinded, RCT, involving a population of 410 female patients.

- **Inclusion criteria**: Adult female patients with facial acne for at least 6 months, judged to warrant oral antibiotics.

- **Exclusion criteria**:
	- Investigator's Global Assessment acne score of 0–1
	- Previous use of spironolactone
	- Use of oral isotretinoin in the past 6 months
	- Use of oral antibiotics for more than one week for acne within the previous month

- **Interventions**:
	- **Spironolactone group (n = 201)**: 50 mg/day until week 6, increasing to 100 mg/day until week 24
	- **Placebo group (n = 209)**: Matching placebo

- **Primary outcome**: Significant increase in improvement in acne-specific QoL symptom subscale score at week 12 (19.2 points vs. 17.8 points; AD 1.27 points, 95% CI 0.07 to 2.46).

- **Secondary outcomes**:
	- Significant increase in improvement in acne-specific QoL symptom subscale score at week 24 (21.2 points vs. 17.4 points; AD 3.45 points, 95% CI 2.16 to 4.75).
	- Significant increase in self-assessed overall improvement score of 3–6 at week 24 (82% vs. 63%; OR 2.72, 95% CI 1.5 to 4.93).
	- Significant increase in Investigator's Global Assessment for treatment success at week 12 (19% vs. 6%; OR 5.18, 95% CI 2.18 to 12.28).

---

### Prevotella and gardnerella are associated with treatment failure following first-line antibiotics for bacterial vaginosis [^1162WKXT]. The Journal of Infectious Diseases (2023). High credibility.

The observed association between recurrence and high abundance of Gardnerella spp and a high BVAB:Lactobacillus ratio immediately posttreatment may also suggest treatment failure due to the presence of a dense biofilm, or alternatively, resistance to first-line therapy, which has been documented for metronidazole. Our finding that high Gardnerella abundance posttreatment may contribute to recurrence is supported by a previous 16S rRNA gene sequencing study of 41 women that found that sustained cure was associated with lower relative abundance of Gardnerella posttreatment. A quantitative polymerase chain reaction (qPCR)–based analysis of the same samples showed that persistently high levels of Gardnerella genomospecies GS07 pre- and posttreatment predicted treatment failure. Furthermore, an analysis of 33 women found that sustained cure at 1 month posttreatment was associated with a marked decrease in Gardnerella vaginalis absolute abundance (quantified using qPCR) following intravaginal metronidazole. Collectively, these data suggest that posttreatment persistence of Gardnerella spp contributes to treatment failure. Metronidazole has limited ability to disrupt established Gardnerella biofilms, and in vitro studies have found that the minimum inhibitory concentration for both metronidazole and clindamycin is higher for biofilm-forming G. vaginalis isolates compared to planktonic isolates. Furthermore, two recent studies both reported that while metronidazole and clindamycin had some in vitro activity against single-species Gardnerella biofilms, neither antibiotic significantly affected treatment outcomes.